Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q1 FY24 results · Apr–Jun 2023
Procter & Gamble Health reported revenue from operations of ₹301.18 crore (up 1.8% from Q1 FY23) and net profit of ₹29.82 crore (down 27.6% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a standalone basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 301.18 | 295.89 | +1.8% | 320.92 | −6.2% |
| Other income | 5.46 | 3.10 | +76.1% | 4.97 | +9.9% |
| Total income | 306.64 | 298.99 | +2.6% | 325.89 | −5.9% |
| Profit before tax | 44.13 | 54.65 | −19.2% | 78.53 | −43.8% |
| Net profit for the period | 29.82 | 41.19 | −27.6% | 59.19 | −49.6% |
| EPS, basic (₹) | 17.96 | 24.80 | not comparable | 35.70 | −49.7% |
| Net margin (%) | 9.9 | 13.9 | 18.4 |
Standalone
- Filed with BSE
- 24 Aug 2023, 13:28 IST
- Board meeting
- 23 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Audited
- Source
- XBRL filing on BSE